IPH

Innate Pharma S.A. occupies an increasingly precarious position in European biotechnology. Headquartered in Marseille and listed on Euronext Paris since 2006, the company has spent more than two decades building one of Europe's most scientifically credible natural killer (NK) cell immunotherapy platforms. And yet, at the analysis date of April 2026, the market capitalization stands at approximately EUR 112 million, the share price trades near EUR 1.20 within a 52-week range of EUR 1.03 to EUR 2.10, and the balance sheet shows negative shareholders' equity of EUR 21.7 million. The gap between scientific ambition and financial reality has rarely been wider.

The central analytical observation is this: Innate Pharma is not a biotech with a moat. It is a biotech with optionality, and optionality has a half-life. Every quarter without a major clinical readout, every dilutive equity raise, and every deferred revenue reversal shortens that half-life further. The 2025 revenue of EUR 2.8 million, down from EUR 51.9 million in 2023, is not a business trend. It is the arithmetic of a company whose income statement depends almost entirely on when and how partners like AstraZeneca, Sanofi, and Novo Nordisk choose to recognize milestone payments.

This creates a structural question that no standard valuation model can resolve. Is Innate Pharma a platform that will eventually deliver a commercialized asset (most plausibly monalizumab through AstraZeneca's INTERLINK-1 and PACIFIC-9 Phase III programs), or is it a research organization that has outlasted its capital base? The answer depends not on internal execution, but on decisions made in Cambridge, Paris, and Copenhagen by partners whose pipelines extend far beyond what Innate contributes. That is the definition of dependency. The framework below examines why Innate occupies this position, how its power core functions despite the dependency, and what trajectories remain credible given the financial constraints now visible on the balance sheet.